PharmaSens Revolutionizes Diabetes Management with Integrated Insulin Patch Pump Study Results

PharmaSens Begins a New Era in Diabetes Management

PharmaSens AG, a Swiss company leading the charge in innovative insulin delivery systems, has recently made headlines with the publication of a pioneering study in the Journal of Diabetes Science and Technology (JDST). This groundbreaking research presents evidence from the first human trial assessing the feasibility of combining insulin delivery and continuous glucose monitoring (CGM) within a single device, the PharmaSens niia insulin patch pump.

The study sheds light on the urgent need for efficient diabetes management solutions. Current systems requiring users to navigate multiple devices can often lead to confusion and increased treatment burden, which can negatively impact glycemic outcomes. With this study, PharmaSens aims to streamline the diabetes management process, providing a device that not only combines functions but is also designed to fit seamlessly into users’ daily lives.

Study Highlights

The feasibility study involved 18 participants, all of whom were living with Type 1 Diabetes (T1D). This trial included a critical phase where 15 participants wore the niia device for 72 hours, undergoing rigorous assessments, including mixed meal tolerance tests and a supervised free-living day. The research aimed to gauge the accuracy and effectiveness of this integrated device compared to traditional glucose monitoring methods.

One pivotal result from the trial indicated that the integrated device achieved an impressive Mean Absolute Relative Difference (MARD) of 11.6% against the reference standard, suggesting promising accuracy for glucose monitoring. For monitoring devices, a MARD of less than 10% is generally ideal, making this result particularly encouraging for those managing diabetes with insulin.

Furthermore, error grid analysis revealed that a significant 83% of readings from the niia device were clinically accurate, while 100% fell within acceptable clinical zones. The absence of insulin delivery failures or adverse events reported during the study adds another layer of validation to the device's safety.

Why Integrated Systems Matter

As highlighted by CEO Marcel Both, today’s diabetes patients seek technology that simplifies their treatment regimen. The significance of the niia device lies not only in its function but in its ability to reduce the complexity of diabetes management. The American Diabetes Association (ADA) recognizes automated insulin delivery (AID) systems as the preferred option for diabetes care. Despite this endorsement, only about 13% of insulin users in Europe and the United States are currently utilizing such systems. The barriers—such as cost, lack of user-friendliness, and technology integration issues—underscore the need for innovation in diabetic care.

“As we aim for widespread adoption, PharmaSens is committed to developing integrated solutions that empower diabetes management while reducing the daily burden on users,” stated Robert Gabbay, MD, PhD, a key advisor for PharmaSens. This vision aligns with the broader goal of healthcare to facilitate improved patient outcomes.

A Future Driven by Innovation

Encouraged by these promising results, PharmaSens is set to commence a second feasibility study in Q2 2026. This next phase will evaluate the next-generation niia insulin patch pump, which aims to integrate more advanced continuous glucose monitoring solutions in collaboration with SiBionics, marking the continuation of PharmaSens’ commitment to innovation in diabetes care.

PharmaSens AG’s determination to transform diabetes management is evident through their extensive research and development efforts over the years. As they prepare to introduce the niia device to broader markets, the healthcare community waits with bated breath, considering the potential impact this integrated device could have on improving the lives of millions of people living with diabetes around the globe.

For more information on PharmaSens and their innovative solutions, visit their website at PharmaSens.com.